Novartis deal on the rocks, page-153

This study is also quite interesting, kind of indicates CRP > 4.6 (MSB used > 4 in their study) is a good predictor of cytokine storm as CRP is linked with IL-6 production. I'm probably getting out of my depth on the science, so I will stop here. But what seems clear is that the CS in C19 has different characteristics to previously defined CS criteria in other diseases.

https://ard.bmj.com/content/annrheumdis/early/2020/09/25/annrheumdis-2020-218323.full.pdf

I don't have issues with the manufacturing. FDA made a balls up in their ADCOM presentation of their backyard lab (no GMP, no SOPs, no validation) claiming they were producing the same MSC's as the company that has spent 2 decades and hundreds of millions of dollars developing the IP and proprietary manufacturing systems. Don't get me started on that hypocritic piece of crap they presented. Poor MSB regulatory lady couldn't cross examine FDA on how they validated any of what they produced.